MARKET

ABCL

ABCL

Abcellera Biologics Inc.
NASDAQ
3.720
+0.030
+0.81%
After Hours: 3.720 0 0.00% 14:21 12/24 EST
OPEN
3.710
PREV CLOSE
3.690
HIGH
3.730
LOW
3.580
VOLUME
1.29M
TURNOVER
--
52 WEEK HIGH
6.52
52 WEEK LOW
1.891
MARKET CAP
1.11B
P/E (TTM)
-6.4539
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ABCL last week (1215-1219)?
Weekly Report · 2d ago
Will AbCellera’s (ABCL) Bruker Patent Settlement and Royalties Shift Its Long-Term Revenue Narrative?
Simply Wall St · 4d ago
AbCellera Biologics Inc. Files Initial Statement of Beneficial Ownership for Director Stephen Quake
Reuters · 4d ago
AbCellera (ABCL) Valuation Check After Bruker Patent Settlement, New Royalty Stream and Legal Overhang Removal
Simply Wall St · 5d ago
AbCellera Secures Global Settlement and Patent License Deal
TipRanks · 5d ago
AbCellera settles patent litigation with Bruker over microfluidic device tech
Seeking Alpha · 6d ago
AbCellera, Bruker Reach Settlement Resolving Patent Litigation
Dow Jones · 6d ago
AbCellera to receive $36M upfront in patent litigation settlement with Bruker
TipRanks · 6d ago
More
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Webull offers AbCellera Biologics Inc stock information, including NASDAQ: ABCL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABCL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABCL stock methods without spending real money on the virtual paper trading platform.